US 12,116,596 B2
Method and apparatus for improved mesenchymal stem cell harvesting
Edward Jeffrey Donner, Fort Collins, CO (US); Christopher Thomas Donner, Fort Collins, CO (US); Ryan Dregalla, Windsor, CO (US); and Lucanus Steven Koldewyn, Johnstown, CO (US)
Assigned to Elite IP, LLC, Johnstown, CO (US)
Filed by Elite IP, LLC, Johnstown, CO (US)
Filed on Apr. 21, 2023, as Appl. No. 18/137,578.
Application 18/137,578 is a continuation of application No. 15/933,314, filed on Mar. 22, 2018, granted, now 11,655,454.
Claims priority of provisional application 62/475,753, filed on Mar. 23, 2017.
Prior Publication US 2023/0250396 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/075 (2010.01); A61K 35/28 (2015.01); C12N 5/0775 (2010.01)
CPC C12N 5/0663 (2013.01) [A61K 35/28 (2013.01); C12N 2509/10 (2013.01); C12N 2527/00 (2013.01)] 31 Claims
 
1. A method of maintaining a patient's health, treating a patient having a medical condition, contributing to a patient's healing and tissue regeneration processes following injury or surgery, or beautifying a patient or client with a solution comprising a micronized autologous biologic scaffold for administration to the patient or client, the method comprising:
obtaining at least one tissue plug or core including autologous cancellous bone from the patient or client with a harvesting tool;
inserting the at least one tissue plug or core into a chamber of a processing device, the chamber not being in fluid communication with the patient or client, the tissue plug or core including autologous calcified bone, trabecular cavities, mesenchymal stem cells (MSC's) and a glycosaminoglycan-rich (GAG-rich) matrix;
adding a fluid to the chamber;
initiating actuation of the processing device thereby causing at least a portion of the autologous GAG-rich matrix to separate from the autologous calcified bone and trabecular cavities and further to be broken mechanically into micronized autologous biologic GAG-rich matrix scaffold particles within the chamber by non-enzymatic processing such that at least a portion of the MSC's remain attached to the micronized autologous biologic GAG-rich matrix scaffold particles in solution with the fluid and wherein the at least a portion of the autologous MSC's retain an anti-inflammatory phenotype following the non-enzymatic processing;
extracting the solution comprising the fluid, the micronized autologous biologic GAG-rich matrix scaffold particles and the at least a portion of the autologous MSC's from the chamber, wherein the solution has a reduced concentration of calcified bone as compared to the tissue plug or core; and
administering the solution to the patient or to the client.